Effect of Androgens on Anemia and Malnutrition in Renal Failure: Implications for Patients on Peritoneal Dialysis

Luke M.C. , Coffey D.S. The male sex accessory tissues: Structure, androgen action, and physiology. In: Knobil E. , Neill J.D. , eds. The physiology of reproduction. New York: Raven Press, 1994: 1435–87.

Bagatell C.J. , Bremmer W.J. Androgens in men: Uses and abuses. N Engl J Med 1996; 334: 707–14.

Bhasin S. , Bremmer W.J. Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997; 82: 3–8.

Manni A. , Parchridge W.M. , Cefalu W. , Nissula B.C. , Bardin C.W. , Santner S.J. Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab 1985; 61: 705–10.

Dunn J.F. , Nisula B.C. , Rodboard D. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53: 56–68.

Mooradian A.D. , Morley J.E. , Korenman S.G. Biological actions of androgens. Endocr Rev 1987; 8: 1–28.

Santulli R. , Sprando R.L. , Awoniyi C.A. , Ewing L.L. , Zirkin B.R. To what extent can spermatogenesis be maintained in the hypophysectomized adult rat testis with exogenously administered testosterone? Endocrinology 1990; 126: 95–101.

Bagatell C.J. , Heiman J.R. , Rivier J.E. , Bremmer W.J. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab 1994; 78: 711–16.

Young N.R. , Baker H.W.G. , Liu G. , Seeman E. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. J Clin Endocrinol Metab 1993; 77: 1028–32.

Bhasin S. , Storer T.W. , Berman N. , Callegani C. , Clevenger B. , Phillips J. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–6.

Bhasin S. , Storer T.W. , Berman N. , Yarasheski K.E. , Clevenger B. , Phillips J. Replacement doses of testosterone increase fat-free mass, muscle size and strength in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407–13.

Shahidi N.T. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72–80.

Ishak K.G. , Zimmerman H.J. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 1987; 7: 230–6.

Soe K.L. , Soe M. , Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12: 73–9.

Slater D. , Parsons A. , Platts M. , Fox M. Peliosis in renal failure treated with androgens. N Engl J Med 1981; 305: 345.

Mokrohisky S.T. , Ambruso D.R. , Hathaway W.E. Fulminant hepatic neoplasia after androgen therapy. N Engl J Med 1977; 296: 1411–12.

Zevin D. , Turani H. , Cohen A. , Levi J. Androgen-associated hepatoma in a hemodialysis patient. Nephron 1981; 29: 274–6.

Thompson P.D. , Cullinane E.M. , Sady S.P. , Chenevert C. , Savitelli A.L. , Sady M.A. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 1165–8.

Tenover J.S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–8.

Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 1991; 151: 1925–33.

Zmuda J.M. , Fahrenbach M.C. , Younkin B.T. , Barsserman L.L. , Terry R.B. , Catlin D.H. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism 1993; 42: 446–50.

Glazer G. , Suchman A.L. Lack of demonstrated effect of nandrolone on serum lipids. Metabolism 1994; 43: 204–10.

Teruel J.L. , Lasunción M.A. , Rivera M. , Aguilera A. , Ortega H. , Tato A. Nandrolone decanoate reduces lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997; 29: 569–75.

Dahlen G.H. , Guyton J.R. , Attar M. , Farmer J.A. , Kautz J.A. , Gotto A.M. Jr. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary disease documented by angiography. Circulation 1986; 74: 758–65.

Scanu A.M. Lipoprotein (a). A genetic risk factor for premature coronary heart disease. JAMA 1992; 267: 3326–9.

Rader D.J. , Hoeg J.M. , Brewer H.B. Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994; 120: 1012–25.

Cressman M.D. , Heyka R.J. , Paganini E.P. , O'Neil J. , Skibinski C.I. , Hoff H.F. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475–82.

Webb A.T. , Reaveley D.A. , O'Donnell M. , O'Connor B. , Seed M. , Brown E.A. Lipids and lipoprotein (a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995; 10: 354–7.

Ozaka M. , Yildirimkaya M. , Bulur M. , Yilmaz K. , Bolu E. , Corakci A. Effects of gonadotropin and testosterone treatment on lipoprotein (a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996; 81: 3372–8.

Berglund L. , Carlstrom K. , Stege R. , Gottlieb C. , Erikson M. , Angelin B. Hormonal regulation of serum lipoprotein (a) levels: Effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996; 81: 2633–7.

Zmuda J.M. , Thompson P.D. , Dickenson R. , Bausserman L.L. Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996; 77: 1244–7.

Lippi G. , Guidi G. , Ruzzenente O. , Braga V. , Adami S. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest 1997; 57: 507–12.

Gascón A. , Belvis J.J. , Berisa F. , Iglesias E. , Estopiñán V. , Teruel J.L. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9: 67–72.

Coffey D.S. Physiological control of prostatic growth. In: Prostate cancer, an overview. UICC workshop on prostate cancer, 1978. Geneva: International Union Against Cancer, 1979: 4–23. (Technical reports series; vol. 48.)

Noble R.L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977; 37: 1929–33.

Bardin C.W. , Swerdloff R.S. , Santen R.J. Androgens: Risks and benefits. J Clin Endocrinol Metab 1991; 73: 4–7.

Teruel J.L. , Aguilera A. , Avila C. , Ortuño J. Effects of androgen therapy on prostatic markers in hemodialysis patients. Scand J Urol Nephrol 1996; 30: 129–31.

DeGowin R.L. , Lavender A.R. , Forland M. , Charleston D. , Gottschalk A. Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone. Ann Intern Med 1970; 72: 913–18.

Richardson J.R. Jr. , Weinstein M.B. Erythropoietic response of dialyzed patients to testosterone. Ann Intern Med 1970; 73: 403–7.

Mayer P.P. , Robinson B.H.B. Testosterone for anaemia in maintenance dialysis. Br Med J 1972; 3: 373.

Davies M. , Muckle T.J. , Cassels–Smith A. , Webster D. , Kerr D.N. Oxymetholone in the treatment of anaemia in chronic renal failure. Br J Urol 1972; 44: 387–94.

Fried W. , Jonasson O. , Lang G. , Schwartz F. The hematologic effect of androgen in uremic patients. Study of packed cell volume and erythropoietin responses. Ann Intern Med 1973; 79: 823–7.

Williams J.S. , Stein J.H. , Ferris T.F. Nandrolone decanoate therapy for patients receiving hemodialysis: A controlled study. Arch Intern Med 1974; 134: 289–92.

Hendler E.D. , Goffinet J.A. , Ross S. , Longnecker R.E. , Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med 1974; 291: 1046–51.

Doane B. , Fried W. , Schwartz F. Response of uremic patients to nandrolone decanoate. Arch Intern Med 1975; 135: 972–5.

Jones R.W.A. , El Bishti M.M. , Bloom S.R. , Burke J. , Carter J.E. , Counahan R. The effects of anabolic steroids on growth, body composition, and metabolism in boys with chronic renal failure on regular hemodialysis. J Pediatr 1980; 97: 559–66.

Neff M.S. , Goldberg J. , Slifkin R.F. , Eiser A.R. , Calamia V. , Kaplan M. A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 1981; 304: 871–5.

Kalmanti M. , Dainiak N. , Martino J. , Dewey M. , Kulkarni V. , Howard D. Correlation of clinical and in vitro erythropoietic responses to androgens in renal failure. Kidney Int 1982; 22: 383–91.

Fried W. , Morley C. Effects of androgenic steroids on erythropoiesis. Steroids 1985; 46: 799–826.

Solomon L.R. , Hendler E.D. Androgen therapy in haemodialysis patients. Br J Haematol 1987; 65: 223–30.

Solomon L.R. , Hendler E.D. Prospective controlled study of androgen therapy in the anemia of chronic renal disease: Effects of iron kinetics. Acta Haematol 1988; 79: 12–19.

Ballal S.H. , Domoto D.T. , Polack D.C. , Marciulonis P. , Martin K.J. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17: 29–33.

Berns J.S. , Rudnick M.R. , Cohen R.M. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37: 264–7.

Dombros N.V. , Digenis G.E. , Soliman G. , Oreopoulos D. Anabolic steroids in the treatment of malnourished CAPD patients: A retrospective study. Perit Dial Int 1994; 14: 344–7.

Teruel J.L. , Marcén R. , Navarro J.F. , Villafruela J.J. , Fernández–Lucas M. , Liaño F. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: A prospective study. Nephron 1995; 70: 282–6.

Teruel J.L. , Aguilera A. , Marcén R. , Navarro J. , García G. , Ortuño J. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Scand J Urol Nephrol 1996; 30: 403–8.

Teruel J.L. , Marcén R. , Navarro J. , Aguilera A. , Fernández G. , Ortuño J. Androgen versus erythropoietin for the treatment of anemia in hemodialysis patients: A prospective study. J Am Soc Nephrol 1996; 7: 140–4.

Gaughan W.J. , Liss K.A. , Dunn S.R. , Mangold A.M. , Buhsmer J.P. , Michael B. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30: 495–500.

Navarro J.F. , Mora–Fernández C. , Rivero A. , Macía M. , Gallego E. , Chahin J. Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Perit Dial 1998; 14: 232–5.

Johansen K.L. , Mulligan K. , Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis. JAMA 1999; 281: 1275–81.

Eschbach S. Anemia of end-stage renal disease (ESRD). Kidney Int 1985; 28: 1–5.

Eschbach S. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35: 134–48.

Van Dyke D.C. , Contopoulos A.N. , William B.S. Hormonal factors influencing erythropoiesis. Acta Haematol 1954; 11: 203–22.

Kennedy B.J. , Gilbertsen A.S. Increased erythropoiesis induced by androgenic-hormone therapy. N Engl J Med 1957; 256: 719–26.

Gardner F.H. , Nathan D.G. , Piomelli S. , Cummins J.F. The erythrothaemic effects of androgens. Br J Haematol 1968; 14: 611–15.

Finkelstein G. , Gordon A.S. , Charipper H.A. The effect of sex hormones on the anemia induced by hemorrhage in the rat. Endocrinology 1944; 35: 267–77.

Steinglass P. , Gordon A.S. , Charipper H.A. Effect of castration and sex hormones on blood of the rat. Proc Soc Exp Biol Med 1941; 48: 169–77.

Crafts R.C. Effects of hypophysectomy, castration, and testosterone propionate on hemopoiesis in the adult male rat. Endocrinology 1946; 39: 401–13.

Lin F.K. , Suggs S. , Lin C.H. , Brown J.K. , Smalling R. , Egie J.C. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580–6.

Eschbach J.W. , Egrie J.C. , Dowing M.R. , Browne J.K. , Adamson J.W. Correction of anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined Phase I and II clinical trial. N Engl J Med 1987; 316: 73–8.

Sundal E. , Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979–87.

Bennett V.M. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991 1: 990–8.

Mirand E.A. , Gordon A.S. , Wening J. Mechanism of testosterone action in erythropoiesis. Nature 1965; 206: 270–2.

Alexanian R. , Vaughn W. , Ruchelman M.W. Erythropoietin excretion in man following androgens. J Lab Clin Med 1967; 70: 777–85.

Fried W. , Gurney C.W. The erythropoietic-stimulating effects of androgens. Ann N Y Acad Sci 1968; 149: 356–65.

Rishpon–Meyerstein M. , Kilbridge T. , Simone J. , Fried W. The effect of testosterone on erythropoietin levels in anemic patients. Blood 1968; 31: 453–60.

Alexanian R. Erythropoietin and erythropoiesis in anemic man following androgens. Blood 1969; 33: 564–72.

Fisher J.W. , Roh B.L. , Halvorsen S. Inhibition of erythropoiesic effects of hormones by erythropoietin antisera in mildly plethoric mice. Proc Soc Exp Biol Med 1967; 126: 97–103.

Yared K. , Gagnon R.F. , Brox A.G. Mechanisms of action of androgen treatment on the anemia of experimental chronic renal failure (Abstract). J Am Soc Nephrol 1997; 8: 633.

Moriyama Y. , Fisher J.W. Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures. Blood 1975; 45: 665–70.

Singer J.W. , Samuels A.I. Steroids and hematopoiesis I. The effect of steroids on in vitro erythroid colony growth: structure/activity relationships. J Cell Physiol 1976; 88: 127–34.

Dainiak N. The role of androgens in the treatment of anemia of chronic renal failure. Semin Nephrol 1985; 5: 147–54.

Byron J.W. Effect of steroids on the cycling of haematopoietic stem cells. Nature 1970; 228: 1204.

Kamamoto T. , Sakoda H. , Yoshida Y. , Uchino H. , Imai N. , Mori K.J. Effects of androgen on transient endogenous spleen colonies and other hemopoietic stem cells in mice. Exp Hematol 1985; 13: 616–22.

Clausters M. , Sultan C. Stimulatory effects of androgens on normal children's bone marrow in culture: Effects on BFU-E, CFU-E, and uroporphyrinogen I synthase activity. Horm Res 1986; 23: 91–8.

Peschle C. , Magli M. , Cillo C. , Lettieri F. , Pizzella F. , Genovese A. Enhanced erythroid burst formation in mice after testosterone treatment. Life Sci 1977; 21: 773–8.

Levere R. , Kappas A. , Granick S. Stimulation of hemoglobin synthesis in chick blastoderms by certain 5 β androstane and 5 β pregnane steroids. Proc Natl Acad Sci USA 1967; 58: 985–90.

Nechles T.F. , Rai U.S. Studies on the control of hemoglobin synthesis: The in vitro stimulating effect of a 5β-H steroid metabolite on heme formation in human bone marrow cells. Blood 1969; 34: 380–4.

Granick S. , Kappas A. Steroid control of porphyrin and heme biosynthesis: A new biological function on steroid hormone metabolites. Proc Natl Acad Sci USA 1967; 57: 1463–7.

Mizoguchi H. , Levere R.D. Enhancement of heme and globin synthesis in cultured human marrow by certain 5 beta H steroid metabolites. J Exp Med 1971; 134: 1501–11.

Abraham P.A. , Macres M.G. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2: 927–36.

Radermacher J. , Koch K.M. Erythropoietin and hypertension. In: Bauer C. , Koch K.M. , Scigalla P. , Wieczorek L. , eds. Erythropoietin: molecular physiology and clinical applications. New York: Marcel Dekker, 1993: 129–44.

Navarro J.F. , Teruel J.L. , Marcén R. , Ortuño J. Improvement of erythropoietin-induced hypertension changing the administration route. Scand J Urol Nephrol 1995; 29: 11–14.

Powe N.R. , Griffiths R.I. , Bass E.B. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. J Am Soc Nephrol 1993; 3: 1660–71.

Gagnon R.F. , Yared K. , Barré P.A. , Brox A.G. Survey of the management of anemia in endstage renal disease (ESRD) (Abstract). J Am Soc Nephrol 1997; 8: 68.

Heide B. , Pierratos A. , Khanna R. Nutritional status of patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Bull 1983; 3: 138–41.

Young G.A. , Young J.B. , Young S.M. , Hobson S.M. , Hildreth B. , Brownjohn A.M. Nutrition and delayed hypersensitivity during continuous ambulatory peritoneal dialysis in relation to peritonitis. Nephron 1986; 43: 177–86.

Goodship T.H. , Lloyd S. , Clague M.B. , Barlett K. , Ward M.K. Whole body leucine turnover and nutritional status in continuous ambulatory peritoneal dialysis. Clin Sci 1987; 73: 463–9.

Marckmann P. Nutritional status of patients on hemodialysis and peritoneal dialysis. Clin Nephrol 1988; 29: 75–8.

Lindholm B. , Alvestrand A. , Fürst P. , Bergström J. Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis. Kidney Int 1989; 35: 1219–26.

Young G.A. , Kopple J.D. , Lindholm B. , Vonesh E.F. , De Vecchi A. , Scalamogna A. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study. Am J Kidney Dis 1991; 17: 462–71.

Cancarini G. , Costantino E. , Brunori G. , Manili L. , Camerini C. , Spitti C. Nutritional status in long-term CAPD patients. Adv Perit Dial 1992; 8: 84–7.

Harty J.C. , Boulton H. , Curwell J. , Heelis N. , Uttley L. , Venning M.C. The normalized protein catabolic rate is a flawed marker of nutrition in CAPD patients. Kidney Int 1994; 45: 103–9.

Cianciaruso B. , Brunori G. , Kopple J.D. , Traverso G. , Panarello G. , Enia G. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1995; 26: 475–86.

Nelson E.E. , Hong C.D. , Pesce A.L. , Petersen D.W. , Singh S. , Pollak V.E. Anthropometric norms for the dialysis population. Am J Kidney Dis 1990; 16: 32–7.

Acchiardo S.R. , Moore L.W. , Latour P.A. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int 1983; 24: 199–203.

Fenton S.S.A. , Johnston N. , Delmore T. , Detsky A. , Whitewell J. Nutritional assessment of continuous ambulatory peritoneal dialysis patients. ASAIO Trans 1987; 33: 650–3.

Lowrie E.G. , Lew L.N. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458–82.

Kopple J.D. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994; 24: 1002–9.

The Canada–USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198–207.

Spiegel D.M. , Anderson M. , Campbell U. , Hall K. , Kelly G. , McCluse E. Serum albumin: A marker of morbidity in peritoneal dialysis patients. Am J Kidney Dis 1993; 21: 26–30.

Avram M.M. , Goldwasser P. , Erroa M. , Fein P.A. Predictors of survival in continuous ambulatory peritoneal dialysis patients: The importance of prealbumin and other nutritional and metabolic markers. Am J Kidney Dis 1994; 23: 91–8.

Lowrie E.G. , Huang W.H. , Lew N.L. Death risk predictors among peritoneal dialysis and hemodialysis patients: A preliminary comparison. Am J Kidney Dis 1995; 26: 220–8.

Avram M.M. , Fein P.A. , Bonomini L. , Mittman N. , Loutoby R. , Avram D.K. Predictors of survival in continuous ambulatory peritoneal dialysis patients: A five-year prospective study. Perit Dial Int 1996; 16(Suppl 1): S190–4.

Malhotra D. , Tzamaloukas A.H. , Murata G.H. , Fox L. , Goldman R.S. , Avasthi P.S. Serum albumin in continuous peritoneal dialysis: Its predictors and relationship to urea clearance. Kidney Int 1996; 50: 243–9.

McCusker F.X. , Teehan B.P. , Thorpe K.E. , Keshaviah P.R. , Churchill D.N. How much peritoneal dialysis is required for the maintenance of a good nutritional state? The Canada–USA (CANUSA) Peritoneal Dialysis Study Group. Kidney Int Suppl 1996; 56: S56–61.

Fung L. , Pollock C.A. , Caterson R.J. , Mahony J.F. , Waugh D.A. , Macadam C. Dialysis adequacy and nutrition determine prognosis in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 737–44.

Chung S.H. , Lindholm B. , Lee H.B. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit Dial Int 2000; 20: 19–26.

Jones M.R. Preventing malnutrition in the long-term peritoneal dialysis patients. Semin Dial 1995; 8: 347–54.

Ikizler T.A. , Wingard R.L. , Hakim R.M. Interventions to treat malnutrition in dialysis patients: The role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Am J Kidney Dis 1995; 26: 256–65.

Wolfson M. Nutritional management of the continuous ambulatory peritoneal dialysis patient. Am J Kidney Dis 1996; 27: 744–9.

Kopple J.D. Therapeutic approaches to malnutrition in chronic dialysis patients: The different modalities of nutritional support. Am J Kidney Dis 1999; 33: 180–5.

Urban R.J. , Bodenburg Y.H. , Gilkison C. , Foxworth J. , Coggan A.R. , Wolfe R.R. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820–6.

Ferrando A.A. , Tipton D.K. , Doyle D. , Phillips S.M. , Cortiella J. , Wolfe R.R. Testosterone injection stimulates net muscle protein synthesis but not amino acid transport. Am J Physiol 1998; 275: E846–71.

Wilson J.D. Androgens. In: Goodman A. , Gilman L. , Rall T. , Murad F. , eds. The pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press, 1990: 1413–30.

Mendenhall C.L. , Moritz T.E. , Roselle G.A. , Morgan T.R. , Nemchawsky B.A. , Tamburro C.H. , for the Veterans Affairs Cooperative Study Group. Protein energy malnutrition in severe alcoholic hepatitis: Diagnosis and response to treatment. JPEN J Parenter Enteral Nutr 1995; 19: 258–65.

Schols A.M. , Soeters P.B. , Mostert R. , Pluymers R.J. , Wouters E.F. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152: 1268–74.

Ferreira I.M. , Verreschi I.T. , Nery L.E. , Goldstein R.S. , Zamel N. , Brooks D. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19–28.

Demling R.H. , DeSanti I. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 1997; 43: 42–51.

Gold J. , High H.A. , Li Y. , Michelmose H. , Bodsworth N.J. , Finlayson R. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996; 10: 745–52.

Grinspoon S. , Corcoran C. , Askari H. , Schoenfeld D. , Wolf L. , Burrows B. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129: 18–26.

Corcoran C. , Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med 1999; 340: 1740–50.

Wilson J.D. , Griffin J.E. The use and misuse of androgens. Metabolism 1980; 29: 1278–95.

Kim M.J. , Kwon K.H. , Lee S.W. Effects of anabolic steroid (AS) on nutritional parameters in malnourished CAPD patients (Abstract). J Am Soc Nephrol 1997; 8: 266.

McNair D. , Lorr M. , Droppleman L. EITS Manual for the profile of mood states. San Diego, CA: Educational and Industrial Testing Service, 1971.

National Kidney Foundation. Clinical practice guidelines for the treatment of anemia of chronic renal failure. In: Dialysis outcomes quality initiative. New York: National Kidney Foundation, 1997.